Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07045194
NA

Virtue® SAB in the Treatment of Coronary ISR Trial

Sponsor: Orchestra BioMed, Inc

View on ClinicalTrials.gov

Summary

A prospective, multi-center, single-blind, randomized (1:1), non-inferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR).

Official title: A Prospective, Multi-center, Single-blind, Randomized (1:1), Non-inferiority Study Comparing Clinical Outcomes of the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) to the AGENT™ Paclitaxel Drug-Coated Balloon (DCB) in the Treatment of Coronary Artery In-stent Restenosis (ISR).

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

740

Start Date

2025-10-20

Completion Date

2032-10

Last Updated

2025-10-29

Healthy Volunteers

No

Interventions

DEVICE

Virtue Sirolimus AngioInfusion Balloon

Percutaneous Coronary Intervention

DEVICE

AGENT™ Paclitaxel Drug-Coated Balloon

Percutaneous Coronary Intervention

Locations (2)

St. Francis Hospital

Roslyn, New York, United States

The Lindner Center for Research at Christ Hospital

Cincinnati, Ohio, United States